RCT | Effects of once-weekly prophylaxis with Efanesoctocog Alfa in patients with severe Hemophilia A

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Once-Weekly Efanesoctocog Alfa Beneficial in Severe Hemophilia A – HealthDay

Commentary on Twitter with a video summary

Efanesoctocog alfa is a new class of factor VIII replacement for hemophilia A that has a longer half-life than other factor VIII products, thus allowing once-weekly dosing. New research findings are summarized in a short video. https://t.co/YuXzifUh8m pic.twitter.com/POCAAfeEni

— NEJM (@NEJM) January 27, 2023